Pulsatile tinnitus (HP:0008629)
Pulsatile tinnitus is generally classified a kind of objective tinnitus, meaning that it is not only audible to the patient but also to the examiner on auscultation of the auditory canal and/or of surrounding structures with use of an auscultation tube or stethoscope. Usually, pulsatile tinnitus is heard as a lower pitched thumping or booming, a rougher blowing sound which is coincidental with respiration, or as a clicking, higher pitched rhythmic sensation.
Synonyms: No synonyms found for this term.
Comment: Pulsatile tinnitus may be associated with vascular abnormalities such as arterioevenous shunts or glomus tumors or the jugular vein, arterial bruits related to a high-riding carotid artery (close to the auditory areas) or carotid stenosis, or venous abnormalities such as a dehiscent jugular bulb or to hypertension. Finally, in some patients, mechanical abnormalities such patulous eustachian tubes, palatomyoclonus (small spasms of muscles in the soft palate area), or idiopathic stapedial muscle spasm may represent the underlying cause of pulsatile tinnitus.
Pubmed References: PMID:23885280
Cross References: MSH:D014012, SNOMEDCT_US:232322006, UMLS:C0751559
KEGG Pathway
| Index | Name | P-value | Adjusted p-value | Odds Ratio | Combined score |
| 1 | Citrate cycle (TCA cycle) | 0.00006056 | 0.001453 | 237.67 | 2308.19 |
| 2 | Thyroid cancer | 0.01471 | 0.07585 | 79.19 | 334.14 |
| 3 | Tryptophan metabolism | 0.01668 | 0.07585 | 69.52 | 284.57 |
| 4 | Cysteine and methionine metabolism | 0.01983 | 0.07585 | 58.14 | 227.95 |
| 5 | Lysine degradation | 0.02493 | 0.07585 | 45.92 | 169.53 |
GO: Biological Process
| Index | Name | P-value | Adjusted p-value | Odds Ratio | Combined score |
| 1 | succinyl-CoA metabolic process (GO:0006104) | 0.001999 | 0.03464 | 713.86 | 4436.86 |
| 2 | glial cell-derived neurotrophic factor receptor signaling pathway (GO:0035860) | 0.001999 | 0.03464 | 713.86 | 4436.86 |
| 3 | Schwann cell differentiation (GO:0014037) | 0.001999 | 0.03464 | 713.86 | 4436.86 |
| 4 | astrocyte development (GO:0014002) | 0.002398 | 0.03464 | 571.06 | 3445.29 |
| 5 | positive regulation of adenylate cyclase activity (GO:0045762) | 0.002797 | 0.03464 | 475.86 | 2797.66 |
GO: Molecular Function
| Index | Name | P-value | Adjusted p-value | Odds Ratio | Combined score |
| 1 | DNA-methyltransferase activity (GO:0009008) | 0.002398 | 0.03235 | 571.06 | 3445.29 |
| 2 | S-methyltransferase activity (GO:0008172) | 0.002797 | 0.03235 | 475.86 | 2797.66 |
| 3 | phosphatidylethanolamine binding (GO:0008429) | 0.003595 | 0.03235 | 356.86 | 2008.48 |
| 4 | kinesin binding (GO:0019894) | 0.01154 | 0.07047 | 101.86 | 454.45 |
| 5 | E-box binding (GO:0070888) | 0.01629 | 0.07047 | 71.26 | 293.40 |
GO: Cellular Component
| Index | Name | P-value | Adjusted p-value | Odds Ratio | Combined score |
| 1 | oxoglutarate dehydrogenase complex (GO:0045252) | 0.001999 | 0.01599 | 713.86 | 4436.86 |
| 2 | axon (GO:0030424) | 0.00005639 | 0.001353 | 59.08 | 577.97 |
| 3 | MLL1 complex (GO:0071339) | 0.01035 | 0.03550 | 114.10 | 521.46 |
| 4 | MLL1/2 complex (GO:0044665) | 0.01035 | 0.03550 | 114.10 | 521.46 |
| 5 | neuron projection (GO:0043005) | 0.001078 | 0.01294 | 21.09 | 144.11 |
Hub genes predicted as biomarkers & predicted FDA approved drugs
| Hub Genes (ranked) | FDA-Approved Drugs |
| MAX | – |
| NF1 | TRAMETINIB, BINIMETINIB, COBIMETINIB, DABRAFENIB, VEMURAFENIB |
| SDHC | – |
| RET | CABOZANTINIB, VANDETANIB |
| SDHAF2 | – |
| KIF1B | – |
| DNMT3A | DECITABINE, IDARUBICIN, WARFARIN |
| DLST | – |
